Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis
暂无分享,去创建一个
[1] P. Tanvejsilp,et al. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas , 2020, Clinical Neurology and Neurosurgery.
[2] K. Kawai,et al. How definitive treatment affects the rupture rate of unruptured cerebral aneurysms: a competing risk survival analysis. , 2020, Journal of neurosurgery.
[3] Thara Tunthanathip,et al. Factors associated with the extent of resection of glioblastoma , 2020, Precision Cancer Medicine.
[4] S. Sangkhathat,et al. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching , 2020, Clinical Neurology and Neurosurgery.
[5] U. Intusoma,et al. Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma , 2020, Journal of Neurosciences in Rural Practice.
[6] Thara Tunthanathip,et al. No association between isocitrate dehydrogenase 1 mutation and increased survival of glioblastoma: A meta-analysis , 2020 .
[7] S. Sae-heng,et al. The First Awake Craniotomy for Eloquent Glioblastoma in Southern Thailand , 2019, Journal of Health Science and Medical Research.
[8] Jennifer S. Yu,et al. Malignant Transformation of Molecularly Classified Adult Low Grade Glioma. , 2019, International journal of radiation oncology, biology, physics.
[9] M. Resche-Rigon,et al. Intracranial WHO grade I meningioma: a competing risk analysis of progression and disease-specific survival , 2019, Acta Neurochirurgica.
[10] T. Oearsakul,et al. Diagnostic Yield and Complication of Frameless Stereotactic Brain Biopsy , 2019, Journal of Neurosciences in Rural Practice.
[11] Jong-Hee Chang,et al. Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification , 2018, Scientific Reports.
[12] Jennifer S. Yu,et al. Risk Factors for Malignant Transformation of Low-Grade Glioma. , 2017, International journal of radiation oncology, biology, physics.
[13] Anshu Gupta,et al. A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016 , 2017, Journal of Neurosciences in Rural Practice.
[14] Jason P Fine,et al. Practical recommendations for reporting Fine‐Gray model analyses for competing risk data , 2017, Statistics in medicine.
[15] Örjan Smedby,et al. Quantitative MRI for analysis of peritumoral edema in malignant gliomas , 2017, PloS one.
[16] Erich P Huang,et al. RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.
[17] Jessica A. Tang,et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. , 2016, Neuro-oncology practice.
[18] Inho Park,et al. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas , 2015, Oncotarget.
[19] Jayesh Sardhara,et al. Multiple glioblastomas: Are they different from their solitary counterparts? , 2015, Asian journal of neurosurgery.
[20] Guo-shi Lin,et al. Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma , 2015, Oncology letters.
[21] R. Sangthong,et al. Free survival time of recurrence and malignant transformation and associated factors in patients with supratentorial low-grade gliomas. , 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[22] A. Laxton,et al. Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? , 2013, International journal of radiation oncology, biology, physics.
[23] Zhi-xiong Lin. Glioma-related edema: new insight into molecular mechanisms and their clinical implications , 2013, Chinese journal of cancer.
[24] B. Bobek-Billewicz,et al. The assessment of prognostic factors in surgical treatment of low-grade gliomas: A prospective study , 2012, Clinical Neurology and Neurosurgery.
[25] A. Baghestani,et al. How to control confounding effects by statistical analysis , 2012, Gastroenterology and hepatology from bed to bench.
[26] M. Berger,et al. GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.
[27] D. Ellison,et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] John P Klein,et al. Modelling competing risks in cancer studies , 2006, Statistics in medicine.
[29] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[30] A. Sav,et al. Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas , 2002, Journal of Clinical Neuroscience.
[31] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[32] M. Faist,et al. Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas , 1997, Cancer.
[33] D. Schoenfeld,et al. Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.
[34] Thara Tunthanathip,et al. Glioblastoma Multiforme Associated with Arteriovenous Malformation: A Case Report and Literature Review , 2020, Annals of Indian Academy of Neurology.
[35] R. Gutierrez. Competing-risks regression , 2010 .
[36] M. McGirt,et al. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. , 2010, Journal of neurosurgery.
[37] B. Iliescu,et al. Malignant transformation of low grade gliomas into glioblastoma a series of 10 cases and review of the literature , 2010 .